Serum interieukin-11 in patients with benign prostatic hyperplasia and prostate cancer
Serum interieukin-11 in patients with benign prostatic hyperplasia and prostate cancer
复制标题
DOI：
10.1007/s11255-004-6086-1
复制
发表时间：
2005-01-01
影响因子：
2
通讯作者：
Fuse, Hideki
中科院分区：
文献类型：
--
作者：
Furuya, Yuzo;Nishio, Remon;Fuse, Hideki
为了阐明血清白细胞介素-11（IL-11）水平是否可以作为前列腺癌患者的有用标志物，在治疗前分别测定了73例前列腺癌和23例良性前列腺增生（BPH）患者的血清IL-11。前列腺癌与BPH患者血清IL-11水平差异无统计学意义。与未经治疗的癌症患者相比，具有抗前列腺癌的患者具有显著更高水平的IL-11。血清IL-11水平可能是前列腺癌进展的潜在肿瘤标志物。
To clarify whether serum levels of interleukin-11 (IL-11) could be a useful marker in patients with prostate cancer, serum IL-11 was determined in 73 and 23 men with prostate cancer and benign prostate hyperplasia (BPH), respectively, before treatment. There were no statistical differences of IL-11 levels between patients with prostate cancer and BPH. Patients with hormone-resistant prostate cancer had a significantly higher level of IL-11 than those with untreated cancer. Serum IL-11 levels may be a potential tumor marker for prostate cancer progression.